-
260 million! Hesco transferred its interest in a new drug for prostate cancer to Haitron Pharmaceuticals.
Time of Update: 2020-09-23
Rights, new technological achievements arising from patented products in China and their co-ownership of supporting property rights, and all rights to clinical trials, drug registration certificates and new drug certificates, research and development rights, production rights, sales rights, commercialization rights, trademarks (generic names) and other intellectual property rights are transferred to Haitron Pharmaceuticals, with a total transfer value of 260 million yuan, to be paid in three installments.
-
NEJM: Conjunctival squamous cell carcinoma - case reported.
Time of Update: 2020-09-23
The patient, an 89-year-old woman, was treated in ophthalmology for 4 months due to redness in her eyes and a foreign object in her right eye.
in follow-up 2 years after surgery, there was no local recurrence.
-
J Exp Med: Lu Jianxin/Lu Zhimin team to reveal a new mechanism of glioma stethocell immune escape.
Time of Update: 2020-09-23
study found that abnormally activated AKT/beta-catenin signals in glioblastomas lead to elevated levels of expression in the immune checkpoint molecule PD-L1 and cause tumor immune escape.
-
Li Wei Reviews . . . TCR-T cell therapy, three major obstacles to be broken.
Time of Update: 2020-09-23
," Kieback said, the company's mouse-sourced TCR is stronger and more specific to cancer antigens than existing TCR-T cell therapy biotechnologies such as Immatics and Adaptimmune.
car proteins to identify tumor targets on the surface of cells, but terabyte tCR only allows cell therapy to kill cells that have cancer stress signals.
-
Cell Death Dis:lncRNA LRRC75A-AS1 promotes the development of triple negative breast cancer.
Time of Update: 2020-09-23
study showed that BAALC promotes cell proliferation, invasion, and endocal-interstrate transformation (EMT) processes, and inhibits TNBC apoptosis.
Reescue rescue experiment also showed that LRRC75A-AS1 in TNBC was able to promote cell proliferation, invasion, and EMT processes by targeting miR-380-3p/BAALC pathps.
-
Professor Wu Jie: What is the relationship between MHT and female malignancies? These questions must be understood!
Time of Update: 2020-09-23
To this end, China Obstetrics and Gynaecology Online invited Professor Wu Jie of Nanjing Medical University First Affiliated Hospital/Jiangsu Provincial People's Hospital on the relationship between MHT and female malignant tumors, the current application of MHT at home and abroad, the risk and benefit evaluation of MHT, the application points of MHT in female malignant tumor survivors, different MHT drugs and different start-up times.
-
J Clin Oncol: Post-study exploration analysis of the ARIEL3 trial.
Time of Update: 2020-09-23
the average Q-TWiST difference between the Rukapali group and the placebo group in the ITT population, BRCA mutation queue, HRD queue and BRCA wild type/LOH low patient group was 6.88 months, 9.73 months, 8.11 months and 3.35 months, respectively, using TOX defined by level 3 TEAE.
-
Cell Death Dis: EphA2 Y772 phosphate is essential for the development of nasopharyngeal cancer.
Time of Update: 2020-09-23
further studies have shown that Shp2/Erk-1/2 signals regulate the proliferation and anchoring of non-dependent growth of pY772-EphA2-mediated NPC cells.
in summary, the study showed that EphA2 protein 772th tyrosine phosphate is essential for the growth of EphA2-dependent nasopharyngeal cancer cells, a process achieved by activating the Shp2/Erk-1/2 signaling path.
-
Hutchison Whampoa launched phase II trials of HMPL-453 for the treatment of advanced liver bile duodenal cancer.
Time of Update: 2020-09-23
, Hutchison Whampoa has begun a Phase II clinical study of HMPL-453 for the treatment of IHCC.
the clinical study is a one-arm, multi-center, open-label Phase II study designed to assess the efficacy, safety, and pharmacodynamics of HMPL-453 in patients with advanced FGFR2 fusion IHCC who failed in at least one systematic treatment.
-
Cell Death Dis:FXR plays a carcinogenic role in colorectal tumors by antagoning the Wnt/beta-catenin signal.
Time of Update: 2020-09-23
study, we looked at the correlation between FXR and Wnt/beta-catenin signal transductivity paths during the development of colorectal cancer.
, the above results show that in colorectal cancer FXR can play its tumor suppression role through an antagonists of the Wnt/beta-catenin signal transduction path.
-
Jingding Pharmaceuticals Global Patient Advisory Committee landed in China to promote patient-centered drug development.
Time of Update: 2020-09-23
currently, Synding Pharmaceuticals has held four patient advisory board meetings in the United States and Europe, working closely with 20 patient consultants worldwide on a variety of clinical diseases, including oncology and rare diseases.
-
PD-L1 monoantial Imfinzi has been approved in Japan to treat a wide range of small cell lung cancer.
Time of Update: 2020-09-23
AstraZeneca's PD-L1 monoantigen-imfinzi (durvalumab) has been approved in Japan to treat patients with extensive stage small cell lung cancer (ES-SCLC) in combination with espressoside and a platinum chemotherapy drug (carbapene or cisplatin).
-
NEJM:Tabrecta treats METex14-jumping non-small cell lung cancer with positive results from key studies.
Time of Update: 2020-09-23
Jeff Legos, head of oncology development at Novart, said: "The data published today not only confirm our previous positive results in the use of Tabrecta in non-small cell lung cancer, but also highlight the value of early and extensive molecular testing of patient tumors to guide treatment options.
-
ESMO 2020: Positive progress has been made in the treatment of relapsed cervical cancer with antibody-drug couple Tisotumab vedotin.
Time of Update: 2020-09-23
Genmab and Seattle Genetics will work together to develop new treatments for advanced cervical cancer." Tisotumab vedotin is being used as a monotherapy or in combination with a variety of commonly used therapies to treat a range of solid tumors as well as relapse and/or metastatic cervical cancer.
-
Nature: Finally know why cancer cells are so "big", it turns out that they are more "grabbing food"
Time of Update: 2020-09-23
further analysis, the researchers determined that the high expression of SLC43A2 in tumors was associated with a decrease in T-cell immune response in cancer patients.
-
Cell Death Dis: Ubiganized modified negative regulator ERR beta promotes the development of breast cancer.
Time of Update: 2020-09-23
same internal and external source experiments have shown that MLN4924, a NEDDylation-specific small molecule inhibitor, restores the expression level of ERR beta and ultimately weakens the proliferation and migration of breast cancer cells.
-
Immunity: Recyclable CAR-T cells are expected to have more powerful anti-tumor effects.
Time of Update: 2020-09-23
On August 18, the Xu Wei Research Group of the Center for Excellence and Innovation in Molecular Cell Science (Institute of Biochemistry and Cell Biology) of the Chinese Academy of Sciences and the Wa
-
J Clin Oncol: MeK1/2 inhibitor Binimetinib's efficacy in treating low-grade slurry ovarian cancer.
Time of Update: 2020-09-23
Low-grade slurry ovarian cancer (LGSOC) is less sensitive to chemotherapy.
post-mortem analysis showed that kraS mutations may affect patients' sensitivity to nitini.
conclusion: Although MEK inhibitors for low-grade slurry ovarian cancer research did not reach their primary endpoint, binitinib also showed anti-tumor activity against LGSOC.
-
First! Four specific antibodies of Leigh Pharmaceuticals were approved for clinical use.
Time of Update: 2020-09-23
According to CDE's official website, a clinical trial of the GNC-038 ivy antibody injection of Baillie Pharmaceuticals has applied for an implied license from the NMPA for the treatment of recurring or recurring non-Hodgkin's lymphoma (R/R NHL), recurring or resuscitated acute lymphoblastic leukemia (R/R ALL) and resuscitable/metastatic solid tumors.
-
Autophagy: Chloroquine combined radiotherapy and temoquine treatment of glioblastoma: Phase IB trial.
Time of Update: 2020-09-23
recently, researchers published the results of a clinical trial in the journal Autophagy, which is the first to explore the safety, pharmacogenetics, and maximum to-to-dosage of chloroquine combined radiotherapy and temoquine in patients with newly diagnosed glioblastoma.
, the maximum daily dose of chloroquine for newly diagnosed glioblastoma patients was 200 mg when combined radiotherapy and temocytamine.
